Region | Design | n | Analyser | Reference standard | CRC sensitivity @ 10 µg/g | CRC specificity @ 10 µg/g | CRC PPV @ 10 µg/g | CRC NPV @ 10 µg/g | |
Terharr sive Droste et al144 | Holland | DTA | 2058 | OC-Sensor | Colonoscopy | 91.1% (84.2% to 95.6%) | 87.0% (85.4% to 83.5%) | – | 99.4% (98.9% to 99.7%) |
McDonald et al68 | UK (Scotland) | DTA | 280 | OC-Sensor | Colonoscopy | 100% (54.1% to 100%) | 93.8% (90.3% to 96.3%) | – | 100% (98.5% to 100%) |
Rodríguez-Alonso et al145 | Spain | DTA | 1003 | OC-Sensor | Colonoscopy | 96.7% (82.8% to 99.9%) | 79.9% (77.2% to 82.3%) | 12.8% (9.1% to 17.9%) | 99.9% (99.3% to 100%) |
Mowat et al64 | UK (Scotland) | DTA | 750 | OC-Sensor | Colonoscopy | 89.3% (71.8% to 97.7%) | 79.1% (75.9% to 82.0% | 14.2% (9.8% to 20.1%) | 99.5% (98.5% to 99.8%) |
Godber et al70 | UK (Scotland) | DTA | 484 | HM-JACKarc | Colonoscopy | 100% (71.5% to 100%) | 76.6% (72.6% to 80.3%) | 9% (5.1% to 15.4%) | 100% (99.0% to 100%) |
95% CIs given in brackets when reported.
CRC, colorectal cancer; DTA, diagnostic test accuracy study; FIT, faecal immunochemical testing; NPV, negative predictive value; PPV, positive predictive value.